- Solutions
Our solutions
- OverviewOur workflow solutions give you the data, tools, and insights to power every decision
- Strategic IntelligenceGet a complete view of strategic issues and stay ahead of emerging disruptive themes
- Sales IntelligenceOur workflow solutions give you the data, tools, and insights to power every decision
- Industry
- Platform
Our platform
Your powerful intelligence platform
Explore the fully comprehensive productivity and insights platform
- Company
We are GlobalData
The contrast between US President Donald Trump and the Democrat nominee Joe Biden’s stances on healthcare are quite stark. While it is not immediately clear whose policies would benefit pharma players more, it appears that the pharmaceutical industry has a clear favorite as it donated $5.9m to Biden’s presidential campaign compared to Trump’s $1.5m donation, […]
Antibodies against SARS-CoV-2 wane over time, suggesting immunity may be short-lived, says GlobalData
Following new data from Imperial College London (ICL) suggesting that antibody levels against SARS-CoV-2 wane over time; Michael Breen, PhD, Director of Infectious Diseases and Ophthalmology at GlobalData, a leading data and analytics company, offers his view: “One of the most salient implications for the new data by ICL, which suggests that antibody levels against […]
Innovate UK prioritizing over 39% of funding to COVID-19 grants demonstrates priority for infectious diseases, says GlobalData
The current COVID-19 pandemic has caused the granting agency Innovate UK to prioritize innovative COVID-19 projects. Infectious disease has become the priority in terms of grant funding for companies, in particular small to mid-size enterprises, says GlobalData, a leading data and analytics company. Innovate UK invested almost £1.5m ($2m) on innovative pharmaceutical research projects in […]
With US election days away, speed of future COVID-19 therapies and vaccine hang in the balance, says GlobalData
The use of Emergency Use Authorizations (EUA) has been deeply polarizing in the US. With only days left until the presidential election, a growing number of pharmaceutical companies are expected to file for emergency use of their products—both therapeutic and prophylactic—to allow for expedited approval and distribution, according to GlobalData, a leading data and analytics […]
A Democratic victory will improve access to telemedicine in rural areas
Telemedicine use in the US increased from the low ten thousands to around 1.3 million patients in 2020, representing more than 100-fold increase, according to GlobalData, a leading data and analytics company. The accessibility and practicality the technology has demonstrated during the pandemic – especially in urban areas – means that it is here to […]
Contract manufacturing organizations slow revenue growth in 2020 could impact the US
Dose contract manufacturing organizations (CMO) contract revenue in 2019 only grew 3.1% compared to 2018 revenue, which is one of the lowest rates since 2012, says GlobalData, a leading data and analytics company. Adam Bradbury, Pharma Analyst at GlobalData, comments: “The dose CMO industry’s revenue growth has slowed this year and continues to grow at […]
Governments need to sort permanent legal solution as telemedicine is here to stay post-COVID-19
With over three-quarters* of US and European healthcare professionals saying they will continue using telemedicine after the COVID-19 crisis ends, governments are under pressure to make telemedicine a standard mode of care. Countries will need to establish consistent and clear legal frameworks for this technology in order to make permanent the temporary changes implemented to support […]
Second wave of COVID-19 vaccines unlikely to be required to improve on protection data of first batch of authorized vaccines
With the US’ Food and Drug Administration’s staging an all-day virtual meeting yesterday (22 October) regarding its planned standards for authorizing a COVID-19 vaccine; Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view: “In the event at least one of the COVID-19 vaccine frontrunners is granted an FDA Emergency Use […]
India’s role in global supply of COVID-19 drugs and vaccines remains crucial despite IPR waiver decision, says GlobalData
Following the news that the US and EU have blocked India’s fight for intellectual property rights (IPR) waiver for COVID-19 drugs; Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “India is already at the center stage for the supply of repurposed COVID-19 drugs. Moreover, Indian vaccine players are […]
Positive data for Amylyx’s AMX0035 strengthen its position to enter ALS market
Following Amylyx’s announcement that AMX0035, its amyotrophic lateral sclerosis (ALS) pipeline drug, showed potential to prolong patient survival in addition to slowing rapid disease progression in the open label extension of Phase II/III clinical trial CENTAUR; Sarah Elsayed, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view on the opportunities and challenges in this market: “The new functional and survival benefits of AMX0035 will significantly strengthen the drug’s position to enter the ALS market over the coming years as a […]
Future uptake of Opdivo and Yervoy combination in oncology is at risk, says GlobalData
Bristol-Myers Squibb’s (BMS) blockbuster combination of Opdivo and Yervoy is facing increasing scrutiny in various oncology indications as to whether the financial burden and clinical toxicity added by Yervoy is worth it. According to leading data and analytics company GlobalData, clinical trials with Opdivo monotherapy outnumber the trials with Opdivo and Yervoy combination. GlobalData has identified that, out of 782 ongoing clinical trials in oncology that have listed Opdivo, Yervoy, or the combination as a primary intervention, Opdivo monotherapy represents the majority. Specifically, 61% of trials include Opdivo monotherapy, 31% of trials the combination, and only 8% include Yervoy monotherapy. Interestingly, only 20% of these trials are industry-sponsored. Sakis […]
MenABCWY vaccines to begin climb to dominance, taking 21% share of 2029’s $3.17bn global meningococcal vaccine market
The launch of pentavalent vaccines from GlaxoSmithKline and Pfizer that protect against the meningococcal serogroups A, B, C, W, and Y (MenABCWY) in the nine major markets (9MM*) are expected to reduce the vaccine burden and be more cost-effective for healthcare systems – thus driving growth in the meningococcal vaccine market over the next ten […]
US 2020 elections to determine the fate of several key reproductive health policies
Reproductive health topics are perhaps some of the most divisive in US politics, with President Donald Trump, and his Democratic opponent, former Vice President Joe Biden, taking vastly different positions on several key issues in this area. Reforms restricting or broadening abortion rights, use of federal funding for abortions, and coverage of contraceptive methods at no out-of-pocket cost, will be influenced by the election outcome. Furthermore, a probable conservative-leaning Supreme Court has triggered […]
Diagnosed prevalent cases of ulcerative colitis to reach 2 million by 2029 in the 8MM
The diagnosed prevalent cases of ulcerative colitis (UC) in the eight major markets (*8MM) are projected to increase from 1.7 million cases in 2019 to 2 million cases in 2029, equating to an annual growth rate (AGR) of 1.36%. The exponential growth in the prevalent cases of UC is attributed to low mortality and increased […]
PAH market forecast to grow at 5% CAGR by 2029, says GlobalData
With recent pipeline approvals of varying mechanisms and an influx of newly diagnosed patients, the pulmonary arterial hypertension (PAH) market is expected to grow at a 5% compound annual growth rate (CAGR) from 2019 to 2029 in the seven major markets*, says GlobalData, a leading data and analytics company. Kajal Jaddoo, Associate Pharma Analyst at […]
Vaccine trials outside home market will help Chinese companies capture Asia and South and Central America markets, says GlobalData
Pharma companies across the globe are working to develop a vaccine against COVID-19, which has already infected more than 38 million globally. Against this backdrop, the Phase III trials conducted by Chinese companies in countries outside China will help Chinese vaccines capture market share in Asian and South and Central American countries, says GlobalData, a […]
Remdesivir price curbing initiates in India make COVID-19 treatment more affordable, says GlobalData
Following the news that the Indian state of Maharashtra has fixed the price of remdesivir; Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “Maharashtra is the worst affected state of the COVID-19 outbreak in India. The state has reported more than 1.55 million confirmed cases and 41,196 deaths […]
Biopharma companies more optimistic about 2020 imports/exports than in Q1, says GlobalData
Senior management of biopharma companies were more optimistic about the COVID-19 pandemic’s effect on imports/exports in Q3 compared to Q1, according to respondents who completed GlobalData’s Pharmaceutical Trade and Supply Chain Survey, fielded in Q3 2020. Fiona Barry at GlobalData comments: “Across all company types and regions, 92% of companies said COVID-19 poses a risk […]
Global Crohn’s disease market set to reach $12.6bn by 2029 driven by new therapies
The Crohn’s disease (CD) market is expected to grow from $7.4bn in 2019 to $12.6bn by 2029 across the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 5.5%, according to GlobalData, a leading data and analytics company. GlobalData’s report, ‘Crohn’s Disease – Global Drug Forecast and Market Analysis to 2029’, states […]
Diagnosed prevalent cases of diabetic retinopathy to reach 17.8 million by 2029 in the 9MM
Diagnosed prevalent cases of diabetic retinopathy in the nine major markets (9MM*) are expected to increase from 14.3 million in 2019 to 17.8 million in 2029, at an annual growth rate (AGR) of 2.4%, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Diabetic Retinopathy – Epidemiology Forecast Report to 2029’, reveals that nearly […]